Navigation Links
Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials

Ace Biosciences, Ace393, the World's First Commercial Vaccine for Travellers' Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Trial confirms good safety profile and strong immunogenicity

ODENSE, Denmark, March 28, 2007 -ACE BioSciences A/S, the infectious diseases company is pleased to announce the successful completion of Phase I clinical trials with its lead product, ACE393, the world's first commercial vaccine for Travellers' Diarrhoea (TD) caused by Campylobacter infection.

ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world. The two stage, double blind, randomised, placebo-controlled trial confirmed that the vaccine was very well tolerated and that the strongest immune response was stimulated by the highest dose when administered in two doses either two or three weeks apart, with 100% of subjects responding. Adverse reactions were transient local site reaction and headaches in some subjects.

Dr Philippe Reboud, (Mediscis Phase I clinical unit) the study_s Principal Investigator commented "These are very satisfying results. The study clearly confirms the vaccine's safety and tolerability. Furthermore, at the 250µg dose, ACE393 stimulates a four fold increase in IgG antibody titre in all subjects, indicating strong immunogenicity (ability to stimulate an immune response). In the past it has proved too challenging to develop an effective vaccine against Campylobacter infection and Travellers' Diarrhoea has been difficult to prevent, leading to the incidence of serious long-term post infection complications such as Guillain Barre Syndrome and reactive arthritis in a few patients. However, thanks to the innovative approach taken by ACE BioSciences, this looks set to change."

Ms Ingelise Saunders, ACE BioSciences, C
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
Post Your Comments:
(Date:7/22/2008)...pment Plan Completed Successfully, DUBLIN, Irelan...ation,plc (NASDAQ: AMRN ) today announced that th...Food and Drug Administration (FDA) to discuss the,...t of,hypertriglyceridemia. Following these discuss...R101 in hypertriglyceridemia., Dr. Declan Doogan,...
(Date:7/22/2008)...and Apidra(R) Resulted in Significant, Reductions ...the Algorithm Use...ults from the "Adjust to,Target in Type 2 Diabetes...,Counting for Adjustment of Mealtime Insulin Gluli...es Association,s (ADA) medical journal,Diabetes C...
(Date:7/22/2008)...herapy and pegylated enzyme produces significan...ne - - Pegylated enzyme well tole.../ -- Halozyme Therapeutics,Inc. (Nasdaq: HALO ),...cializing products targeting the extracellular mat...pre-clinical animal efficacy data,for its pegylate...
(Date:7/22/2008)...2 /- NicOx S.A.,(Euronext P...pleted the,enrollment of 417 osteoarthritis (OA) p...al pharmacology studies in the United States, in l...als are designed to assess the,blood pressure prof...,naproxen, using the Ambulatory Blood Pressure Mon...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 1Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 2CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 1CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 1Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 3Free Egg Donor Contest Ending March 31 14421 1Free Egg Donor Contest Ending March 31 14421 2
(Date:7/25/2008)... Whether you are an Olympian, Professional ...re Five Things You Need to Know about Hydration to... and Sports Center , Mari...a,s premier athletes are heading to Beijing follow...crifice in the hopes of capturing an Olympic medal...
(Date:7/25/2008)... This donation will be used to facilitate t...es for children , Hauppau...ci.com ), a leading integrator of enterprise coll...o conferencing, telepresence, audio visual integra... today that it has donated video conferencing equi...
(Date:7/24/2008)..., N.C. Researchers at Wake Forest University Bap... clinical belief that the hepatitis C virus slows ...tself after HIV patients are treated with a combin...itis C (HCV) infection is more serious in HIV-infe...ing to the Centers for Disease Control. Intravenou...
(Date:7/24/2008)...ly 24 /PRNewswire-USNewswire/ -- Speaker Nancy Pel...in support of the Tom Lantos,and Henry J. Hyde Glo...,Malaria Reauthorization Act of 2008. The bill, wh...this evening by a vote of 303 to 115 and will now ...day the House took an historic vote to pass landma...
Breaking Medicine News(10 mins):Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
...treating tissue at the back of the mouth is succes...en and 30 per cent of women have a problem with sn...em is vibrations in the soft palate - the area of ...la, the sides of the tonsils, and the base of the ...
...ften have gastrointestinal symptoms such as incont...frequent stomach and intestinal troubles may be a ...a side effect of diabetes medications, researchers...tburn, bloating, nausea, vomiting, diarrhea and co...
...tember 11 terrorist acts in New York and Washingto...put on hold for several days, which severely affec...ceuticals. Most radiopharmaceuticals are shipped v...hese products are either radioactive themselves or...
... Administration has approved the first hormone-rel...ganon, Inc., effectively blocks conception between...that for every 100 women who use it for a year, on... That rate is similar to both the birth control pi...
Other Medicine News:
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: